IRF-5 is a transcription factor activated by toll like receptor (TLR)7 and TLR9 during innate immune responses. IRF-5 activates not only Type I IFN, but also inflammatory cytokines. Most importantly, a genetic variation in the IRF-5 gene shows a strong association with autoimmune diseases such as Lupus. Here, we report that IRF5-deficient mice have attenuated IgG2a/c responses to T-celldependent and -independent antigens and to polyoma virus infection. This defect is due to the intrinsic deletion of IRF-5 in B cells, as SCID mice reconstituted with Irf5 À / À B cells show a decrease in IgG2a/c expression after viral infection compared with mice that received wild-type B cells. Irf5 À / À B cells in vitro have diminished TLR and cytokine-induced class switching to IgG2a/c. Addressing the molecular mechanism, we show that IRF-5 regulates IgG2a/c expression by decreasing Ikaros expression; reconstitution of IRF-5 in Irf5 À / À B cells downregulates Ikaros levels and increases switching to IgG2a/c. The IRF site in ikzf1 promoter binds IRF-5, IRF-4 and IRF-8. We show that IRF-8 but not IRF-4 activates the ikzf1 promoter, and IRF-5 inhibits the transcriptional activity of IRF-8. Collectively, these results identify the IRF-5-Ikaros axis as a critical modulator of IgG2a/c class switching.
INTRODUCTION IRF-5 is a transcription factor that has an important role in the induction of Type I interferon (IFN) and inflammatory cytokines. The interferon regulatory factor (IRF) family consists of nine cellular IRFs, 1, 2 and two of these, IRF-3 and IRF-7, have a major role in the transcription of IfnA and IfnB genes. In vitro studies have indicated that IRF-5 may be also involved in the antiviral response, 3 and the importance of IRF-5 in the antiviral and inflammatory response in vivo was clearly demonstrated in Irf5 À / À mice. Irf5 À / À mice exhibit high susceptibility to vesicular stomatitis virus (VSV) and herpex simplex virus (HSV)-1 infection, show reductions in serum levels of type I IFN as well as inflammatory cytokines. 4 ,5 IRF-5 is expressed in B cells, DC, monocytes and macrophages and in contrast to IRF-3 and IRF-7, IRF-5 is activated by toll like receptor (TLR)7 and TLR9 MyD88-dependent pathways, but not by TLR3 or RIG I-mediated pathways. 6 The MyD88-mediated activation of IRF-5 involves the formation of a tertiary complex consisting of MyD88 tetramers, IRAK1, IRAK4, TRAF6 and IRF-5 and/or IRF-7. 7 K 63 ubiquitination by TRAF6 and phosphorylation are necessary, for the nuclear translocation of IRF-5. 3, 8 In humans, IRF5 is expressed as multiple spliced variants 9 and a distinct polymorphism (rs 2304256) in IRF-5 was shown to be associated with autoimmune diseases such as systemic lupus erythematosis (SLE), 10 rheumatoid arthritis 11 and others. 12 Dysregulated expression of type I IFN is a hallmark of autoimmune diseases. 13 Interestingly, although both IRF-3 and IRF-7 have a critical role in Type I IFN induction, they are generally not associated with predisposition to autoimmune diseases. Thus, IRF-5 is possibly the most important IRF-triggering inflammatory diseases. Mouse models of SLE provide additional information on the possible role of IRF-5 in SLE pathogenicity. FcRIIB À / À mice develop spontaneous lupus, characterized by the production of chromatin-specific autoantibodies. TLR9 and IRF-5 have a critical role in the development of anti double-stranded DNA antibodies 14 and SLE. 15 We have shown that in addition to a decreased production of type I IFN and inflammatory cytokines, Irf5 À / À mice exhibit an altered B-cell phenotype, manifested by an age-related expansion of CD19 þ B220 À B cells, splenomegaly and a decrease in Blimp-1 expression and plasma cells. 16 The aim of this study is to further understand the role of IRF-5 in B-cell responses to antigens and class switch DNA recombination (CSR). We show attenuation of the IgG2a/c responses to T-cell-independent (TI) and T-celldependent (TD) antigens as well as to viral infection in Irf5 À / À mice in vivo and decreased CSR to IgG2a/c in Irf5 À / À B cells in vitro. To address the molecular mechanism of this defect, we show that IRF-5 regulates CSR to IgG2a/c by modulating the expression of the transcription factor Ikaros that is essential for allelic exclusion at the Igk locus. Thus, our data are consistent with a B-cell-intrinsic role of IRF-5 in promoting the expression of IgG2a/c, an antibody isotype that is important in antiviral responses and also in autoimmune pathology.
RESULTS
Defective humoral immune response in Irf5 À / À mice In this study, we used the Irf5 À / À mice that were 98% C57BL6/J genotype and Irf5 cre/cre mice that were 100% C57BL6 (described in Materials and methods). To test whether the lack of IRF-5 affects antigen-specific antibody responses, we first examined the ability of IRF-5-deficient mice to generate IgG responses to TD and TI antigens and viral infection. In response to immunization with NP-KLH, a TD antigen, IgM, IgG1 and IgG2a/c responses were all significantly lower in Irf5 À / À mice compared with wild-type (WT) or heterozygotic Irf5 À / þ mice. The most striking difference was seen in serum levels of IgG2a/c, which were almost undetectable in Irf5 À / À mice. The decrease in IgG2a/c expression was also seen in immunized Irf5 cre/cre mice, (Figure 1a ). IgG2a/ c responses to immunization with NP-LPS, a TI antigen were also diminished in Irf5 À / À mice compared with WT mice (Figure 1b) . Altogether, these results show that IgG2a/c responses to TD and TI antigens are attenuated in Irf5 À / À mice, indicating that IRF-5 has a major role in effective antigen-specific IgG2a/c responses. Attenuated responses to TD antigens, with a major decrease in the IgG2a/c response was also shown in MyD88 À / À mice.
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IgG2a/c is a predominant isotype of many antiviral antibody responses.
18 Irf5 À / À mice also have decreased IgG2a/c responses to virus infection (Figure 1c) . The virus-specific antibody responses of WT and Irf5 À / À mice to the major polyoma virus (PyV) capsomer protein VP1 were measured 28 days after infection with the PyV. The VP1-specific enzyme-linked immunosorbent assay (ELISA) showed greatly reduced IgG2a/c levels, but the difference in levels of antiviral IgG1 was small (Figure 1c ). The changes in the isotype distribution of the antiviral IgG in Irf5 À / À mice were similar to the ones observed in PyV-infected MyD88 À / À mice, that also exhibited decreased IgG2a/c levels.
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Adoptive transfer experiments confirmed that the attenuated IgG2a/c response to virus infection is an intrinsic property of Irf5 À / À B cells. Rag1 knockout mice were reconstituted with B cells from WT or Irf5 À / À mice together with purified WT T cells. The two groups of mice, which differed only in their B-cell population, were infected with PyV. Results in Figure 1d show that the serum levels of PyV-specific IgG were significantly lower in mice reconstituted with Irf5 À / À B cells than with B cells of WT mice. Also the percentage of IgG2a-positive B cells present in spleens of mice reconstituted with Irf5 À / À B cells were significantly lower than in mice reconstituted with WT B cells (Figure 1e ). These data show that the defective IgG2a/c responses in virus-infected Irf5 À / À mice are mostly due to the absence of IRF-5 expression in B cells.
It was observed recently (M Diamond, personal communication) that the Irf5 À / À C57BL6 (98% C57BL/6) mice carry a mutation in the Dock2 gene associated with the decrease in marginal zone B cells. However, the Irf 5 cre/cre mice do not carry the Dock2 mutation (data not shown), and levels of marginal zone B cells in the Irf5 cre/cre mice were comparable to WT mice, but the percentage of IgG2a/c-expressing B cells was significantly decreased in comparison with WT B cells (Supplementary Figure 1B) . Our preliminary data have also shown that the ACS À / À mice that have defect in Dock2 expression 20 and a decreased levels of MZ B cells do not show down modulation of antigenic response to IgG2a (data not shown). Thus, the defect in IgG2a responses is due to the lack of IRF-5, and independent of a mutation in DocK2. This conclusion is further supported by ectopic IRF5 expression experiments (see in Figure 4d ).
IRF-5 regulates CSR in mature B cells
We have shown that the Irf5 À / À mice have defect in the IgG2a/c responses to antigens. We, therefore, asked if IRF-5 is required for cytokine and TLR-induced class switching (CSR) of mature B cells in culture. As CSR can be induced in B cells in vitro by combination of B-cell activators, including TLR ligands and cytokines, 21 purified B cells from spleens of naive Irf5 À / À and WT mice were cultured with lipopolysaccharides (LPS) alone or in combination with interleukin (IL)-4, IFNg or TGFb that induces preferential switching to IgG3, IgG1,IgG2a/c or IgG2b, respectively 22 ( Figure 2a ). (Figure 2b ). Altogether, these data indicate that IRF-5 has a critical function in the regulation of cytokine and TLR-induced CSR to IgG2a/c in mature B cells.
Analysis of germline transcripts (GLT) in Irf5 À / À deficient B cells CSR requires transcriptional activation of the non-coding GLT of the respective IgG isotypes. 21 To determine whether IRF-5 affects CSR-induced GL transcription, we compared the induced levels of GL IgG transcripts in freshly purified Irf5 À / À B cells and WT controls. The results in Figure 3a showed that GL g1 transcripts were detected only in LPS and IL-4-stimulated cells, but their levels were profoundly higher in Irf5 À / À B cells than in the controls. Also the relative levels of levels GL g3 transcripts were higher in LPS-stimulated Irf5 À / À B cells than in WT cells. However, in LPS-and IL-4-stimulated Irf5 À / À B cells relative levels of GL g2 transcripts were significantly lower than in WT B cells. These data indicate that IRF-5 is important for the stimulation of GL g2 transcription, whereas it suppresses transcription of g1 and g3 GLT.
LPS and IFNg, R848 or CpG, are all good inducers of IgG2a/c. As the GL IgG2a/c transcripts are less abundant than the GL IgG1or IgG3 transcripts, 23 we used nested PCR for g2 GLT detection. GL IgG2a/c transcripts were not detected in unstimulated B cells. Role of IRF-5 in the regulation of activation-induced cytidine deaminase (AICDA), T bet and IRF-4 The expression of AICDA is critical for CSR 24 and there is a correlation between relative levels of Aicda transcripts, protein and the efficiency of CSR. However, expression of Aicda was not downregulated in Irf5 À / À B cells (Supplementary Figure 2) and in TLR-stimulated Irf5 À / À B cells (with exception of TLR7) the levels of Aicda were higher than in the WT B cells (Supplementary Figure 2) . Altogether these results show that the decreased in CSR to IgG2a in Irf5 À / À B cells is not caused by Aicda deficiency. Interestingly, an increase in AICDA expression was also observed in Ikaros knockout B cells. 25 The IgG2a class switching is attenuated in T-bet-deficient B cells. 26 We have therefore examined T-bet expression in purified Irf5 À / À B cells. The results (Figure 4a and Supplementary Figure 2) showed no significant downregulation of T-bet expression in stimulated Irf5 À / À B cells compared with WT B cells. The kinetics of T-bet expression early after the CpG induction showed a delay in T-bet expression during the first 12 h after induction in Irf5 À / À B cells (data not shown). However, at 24 h after induction T-bet expression was not significantly different between the two genotypes. These results show that the downregulation of IgG2a/ c expression is not a consequence of T-bet deficiency.
Transcription factor IRF-4 controls B cell CSR and plasma cell differentiation. 27 We have therefore examined whether 
IRF-5, controls the expression of IKAROS in B cells
The zinc-finger transcription factor Ikaros is required for B-cell differentiation and allelic exclusion at the Igk locus. 28 Although ikzf1 (Ikaros) À / À mice do not develop B cells, Ikaros L/L mice are hypomorphic and have B lymphocytes in relatively normal numbers. B cells of these mice also show increased serum levels of IgG2a and IgG2b, increased CSR to IgG2a and IgG2b and attenuated IgG1 responses. 29, 30 We therefore asked whether IRF-5 controls Ikaros expression or function and analyzed relative levels of ikzf1 transcripts in stimulated Irf5 À / À and WT B cells. (Figure 6a-c) . We have shown previously that ectopic MyD88 activates IRF-5; 5, 6, 8 therefore, the cells were transfected with IRF-5 in the presence and absence of MyD88 expression plasmid. The lysates of transfected cells were used in the DNA pull-down assay. The results showed that only the MyD88-activated IRF-5 bound effectively to deoxyoligonucleotides corresponding to the IRF-IK site (Figure 6a ). Also both IRF-4 and IRF-8 bound specifically to the IRF-IK site and their binding was not dependent on the expression of MyD88 (Figures 6b and c,  respectively) . None of these factors bound to a scrambled deoxynucleotide (Supplementary Figure 3) . We also examined whether these two factors can compete binding of IRF-5. DNA pull-down competition showed that IRF-4 (Figure 6b ), but not IRF-8 (Figure 6c ), compete IRF-5 binding to the IRF-IK.
IRF-4 and IRF-8 were shown to stimulate Ikaros expression in B cells. 31 We, therefore, used the ChIP assay to compare their binding to the ikzf1 promoter in purified WT and Irf5 À / À B cells in vivo (Figure 6d IRF-5 and IRF-8, but not IRF-4, stimulates the transcriptional activity of the ikzf1 promoter To examine whether IRF-4, IRF-5 and IRF-8 stimulate transcription of ikzf1, we have used a transient transfection assay. The individual IRFs were transfected together with the ikzf1 promoter-luciferase reporter and MyD88 into HEK293T cells. In the presence of MyD88, both IRF-5 and IRF-8 stimulated activation of ikzf1 promoter, whereas in the absence of MyD88, neither IRF induced any significant activity (Figure 7) . IRF-4 either alone or in the presence of MyD88 was unable to stimulate the ikzf1 promoter. It was shown that IRF-4/Pu.1 heterodimer activates genes containing a binding site composed of an IRF-ETS element; 32 however, in the ikzf1 promoter the PU.1 sites are far away from the IRF-IK site and co-transfection of IRF-4 with Pu.1 did not activate the ikzf1 promoter. IRF-4 was shown to activate Blimp-1 in T regulatory cells; 33 however, in a transient transfection assay IRF-4 did not activate Blimp-1 promoter, whereas as shown previously IRF-5 was an effective activator 16 (data not shown). These data indicate that the transcriptional activity of IRF-4 is cell type-specific and it is negligible in the 293T cells. Interestingly, although IRF-5 alone activated the ikzf1 promoter, when co-transfected with IRF-8, IRF-5 inhibited the IRF-8-mediated stimulation. The IRF-5-mediated inhibition is not due to the competition for the binding to the IRF-IK-binding site (Figure 6d ),or due to the formation of IRF-5/IRF-8 heterodimers (Supplmentary Figure 4) . The mechanism of IRF-5-mediated downregulation of IRF-8-stimulated transcription is under investigation.
Irf7 À / À mice IRF-7 has a major role in antiviral responses, 34 but its role in differentiation and function of lymphoid cells has not been established. As the MyD88 signaling pathway activates both IRF-5 and IRF-7, we examined whether IRF-7 has any role in the induction of TD antibody responses. However, Irf7 À / À mice immunized with NP-KLH showed no difference in serum levels of IgG1, IgG2a/c and IgM responses compared with WT mice (Supplementary Figure 5A) .
We also examined whether IRF-7 is required for the cytokine and TLR-induced CSR of mature B cells. However, there was no significant decrease in the relative levels of IgG2a/c and IgG2b in Irf7 À / À and WT B cells (Supplementary Figure 5B) , indicating that IRF-7 does not have a major role in CSR. Collectively, these data show that IRF-7, which is expressed in B cells at very low levels, has very little, if any, role in B-cell responses to TD-dependent antigen and TLR-and cytokine-induced CSR. Thus, IRF-5 seems to have a major role in MyD88-mediated B-cell immune responses without a major contribution by IRF-7. This is in contrast to DC, where induction of IFNa and IL-6 by TLR7 and TLR9 agonists was dependent both on IRF-5 and IRF-7. 35 The stimulation of the TLR7 signaling pathway has been used to boost the immune response in various vaccines. 36 The finding that the TLR7-mediated stimulation of B-cell activation is entirely dependent on the activation of IRF-5 indicates that the enhancement of the B-cell immune response is independent of IRF-7.
DISCUSSION
This study clearly demonstrates that IRF-5 has a critical role in B-cell function. Inactivation of IRF5 leads to an altered isotope switching, resulting in greatly diminished IgG2a/c responses to various antigens and to virus infection. Our novel finding is that the modulation of the IgG2a/c responses is mediated by the IRF-5-Ikaros axis. The defect in both TI and TD responses was highly specific for IgG2a/c, indicating that IRF-5 has a direct role in the pathways leading specifically to the expression of IgG2a, an antibody isotype important in antiviral responses and in autoimmune pathology. Mice defective in MyD88 were reported to mount reduced IgG responses to infections with Influenza virus and PyV, reduced IgG2a and IgG2b, and unchanged or increased IgG1. 19 Our findings, showing that IRF5 acting downstream of MyD88 has an essential role in regulating isotype switching, provides a mechanistic explanation for these observations. The IRF5 dependence of GL g2a transcription was profound in TLR7 and TLR9-stimulated B cells, whereas the GL transcription of g2 in LPS and IFNg-stimulated B cells was less-dependent on IRF-5. Interestingly, deficiency in IRF-5 expression resulted in an increase of g1 and g3 GL transcripts and decrease in g2 GL transcripts in LPS or LPS and IL-4-stimulated Irf5 À / À B cells. Thus, IRF-5-modulated switching of IgG isotypes in vitro, depends on the stimulation protocol. Previously, binding of IRF-5 to the IRF element was observed in the promoter region of the y2 gene, suggesting that IRF-5 directly regulates IgG2a/c transcription. 37 Transcription factor T-bet was shown previously to have a central role in the TI-induced IgG2a autoantibodies. 26 In vitro, T-bet is induced in B cells in the context of LPS and CD40 ligation as well as by stimulation with IFNg. 38 Our finding that the levels of T-bet are not greatly down-modulated in Irf5 À / À B cells undergoing CSR indicates that downregulation of T-bet expression is not responsible for attenuated IgG2a/c expression. An earlier study 37 described a decrease in T-bet expression in CpG-stimulated Irf5 À / À B cells. This difference can be reconciled by the observation that the early induction of T-bet expression is delayed in CpG-stimulated Irf5 À / À B cells (data not shown) when compared with WT B cells. It was shown that induction of T-bet by CpG is strongly enhanced by IL-12. 39 This enhancement may be initially less effective in Irf5 À / À B cells, in which expression of IL-12 is downregulated. 5 Several lines of evidence indicate that IRF-5 mediates induction of IgG2a by regulating Ikaros expression. Ikaros family transcription factors can silence the expression of their target genes via recruitment of transcriptional repressor complexes such as histone deacetylase complexes. 40 Mice lacking ikzf1 gene do not develop B cells, therefore the role of Ikaros in mature B cells has been characterized by the analysis of mice expressing hypomorphic ikzf1 mutant. These mice showed enhanced expression of IgG2a/c and IgG2b and decreased expression of IgG1 during LPS-and IFNg-induced CSR in culture. 30 These results identified Ikaros as a critical factor controlling the isotypes targeted by CSR. Our finding that the relative levels of ikzf1 transcripts were increased in Irf5 À / À B cells undergoing CSR suggested that ikzf1 expression is under IRF-5 control. Consistent with this notion, we have shown that reconstitution of IRF-5 expression in Irf5 À / À B cells downregulated Ikaros levels and rescued expression of g2 GL transcripts. By sequence analysis we identified an IRF-binding site Both IRF-4 and IRF-8 have critical functions in the B-cell differentiation program. IRF-4 regulates IgG class switching and plasma cell development. 41, 42 Also, stimulation of ikzf1 expression in B cells by IRF-4 and IRF-8 was previously observed. 31 The inability of IRF-4 to activate the ikzf1 promoter was unexpected, since we detected IRF-4 binding to ikzf1 promoter both in vitro and in vivo. It was shown previously that IRF-4/Pu.1 heterodimer activates genes containing an IRF-ETS composite element; 32 however, the ikzf1 promoter does not contain this composed site and the co-transfection of IRF-4 with Pu.1 did not rescue transcriptional activity of IRF-4. These data indicate that IRF-4 can bind to the IRF-IK-binding site, but the association with Pu.1 in the ETS composed element or another lymphoid cell-specific transcription factor may be required for its transcriptional activity. The upregulation of IRF-4 transcripts in Irf5 À / À B cells stimulated with TLR7 and TLR9 agonists that activate IRF-5; however, this enhancement has to be yet confirmed by real-time PCR analysis. IRF-5 and IRF-4 compete for binding to MyD88, 43 and this competition is absent in TLR-stimulated Irf5 À / À cells. MyD88 controls mRNA stability through its death domain-associated kinase. 44 Thus, the increased binding of IRF-4 to MyD88 in Irf5 À / À B cells may result in a post-transcriptional stabilization of IRF-4 mRNA. This possibility is currently under examination. Altogether, these data indicate that several members of the IRF family can affect B-cell development. Redundancy between factors within one family is common; however, the strong genetic association between IRF-5 and autoimmune diseases points out to a unique function of IRF-5 in the immune system.
The activation of IRF-5 by the MyD88 pathway, is required both for binding of IRF-5 to the ikzf1 promoter and its transcriptional activity. The question therefore arises as to what activates IRF-5 in B cells of naïve mice. Although this has to be yet examined in details, the observation that naïve Tlr7 knockout mice have lower levels of IgM and IgG suggests that TLR7 may be constitutively active in B cells. 45 Also the immune complexes present in sera of SLE patients can activate IRF-5 in macrophages. 46 Whether IRF-5 can be activated by similar mechanism in B cells is yet to be determined. Finally, the role of the microorganisms in the activation of IRF-5 and, consequently, Type I IFN signature needs to be addressed and its contribution to pathogenesis of the autoimmune disease needs to be evaluated. 47 In summary, in this study we have elucidated a new link between IRF-5 expression and the regulation of B-cell function. The previously unappreciated role of IRF-5-in the isotype class switch to IgG2a/c provides mechanism linking the IRF-5 Ikaros axis to CSR and its possible acceleration as seen in SLE patients. 48 One of the hallmarks of SLE, is B-cell activation, and the generation of plasma cells producing autoantibodies. 49 Given the ubiquitous nature of IRF DNA binding, the evidence presented here on the role of IRF-5 in the regulation of Ikaros expression is a novel observation that may be especially relevant to SLE. The association between enhanced expression of IRF-5 with a distinct polymorphism and increased risk of SLE has been well documented, and recently an association of IRF-8 and IRF-7 with pathogenicity of SLE was also observed. 50 Genome-wide expression studies have identified many important genetic loci that increase risk for inflammatory disease. The transcriptional signature of genes, associated with the type I IFN response is a common feature of these diseases and may indicate contribution of the microorganism to the pathogenesis. Thus, a given disease may be caused not by one, but multiple mechanisms formed by the interactions between the genetic risk factors and the host microorganism. 47 The association of IRF-5 with many forms of autoimmune disease indicates its critical function in the pathogeneses of this disease.
MATERIALS AND METHODS Mice
Irf5 À / À mice originally obtained from Dr Tak Mak, (Irf5 À / À N6), were back-crossed to C57BL/6 mice for at least 10 generations (described in details in Supplementary Information). The Irf5 cre/cre mice were generated by Ozgene (Perth, WA, Australia); the cre gene was under regulation of the phosphoglycerate kinase promoter, which results in a total deletion of IRF-5 (Supplementary Figure 1) . Animal housing, mice breeding and all experiments were carried out in compliance with protocols approved by The Johns Hopkins University Animal Use and Care Committee and the University of Massachusetts Medical School Animal Care and Use Committee. The genetic backgrounds of Irf5 À / À mice were assessed at DartMouse as described in Supplementary Information.
Expression plasmids
pcDNA6 Myc/His-tagged murine IRF-5 plasmid was described previously.
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MyD88 expression plasmid was obtained from Dr K Fitzgerald. IRF-4 expression plasmid and the retroviral vector carrying murine IRF-5 cDNA and GFP gene were obtained from Dr R Lu. 31 For the construction of IkarosLuciferase reporter plasmid, the ikzf1 promoter was amplified from mouse genomic DNA using primers 5 0 -GATCGGTACCCATTAGCTGCCGATGCCTGT- reporter (40 ng) was transfected with Renilla luciferase plasmid (10 ng) to normalize the transfection efficiency. Luciferase activity was measured using the dual luciferase assay system (Promega).
Polyclonal antibodies against IRF-4, IRF-8, Pol II and monoclonal antibodies against IRF-5 were purchased from Santa Cruz Biotechnology (San Diego, CA, USA). Anti-rabbit IRF-5 antibodies were generated in rabbits against the VRFPSPEDIPSDKWR peptide by Affinity BioReagents. 5 B-cell isolation, CSR stimulation and Immunoglobulin isotyping and RT-PCR Naive resting B lymphocytes were isolated from spleens by negative selection with CD43 microbeads (Miltenyi Biotech, Auburn, CA, USA). For CSR induction, 10 6 purified B cells (97% pure) were cultured with TLR ligands LPS, R848 and CpG and cytokines IL-4, IFNg or TGFb for 4 days and immunoglobulin isotypes were analyzed by ELISA as described in Supplementary Information. Titers were calculated from linear regression curves and are expressed in ELISA units per milliliter. Cells collected 2 days after stimulation were analyzed by FACS. Primers used are listed in Supplementary Table 1. Immunization, PyV infection and analysis of serum IgG isotypes by ELISA Irf5 À / À and C57BL/6 mice (6-8 weeks old from the same litters) were immunized with NP-KLH with Imject alum, NP-LPS or NP-FICOL and the antigen-specific titers in serum were determined at 7 or 14 days after immunization. Mice were also infected intraperitoneal with PyV strain A2 and tail-bled at 4 weeks after infection. PyV capsid protein-specific antibody production was determined with purified recombinant VP1.
Adoptive transfer
MACs-purified splenic B cells from C57BL/6 or Irf5 À / À mice (10 7 cells per mouse) were intravenously transferred into Rag1 KO mice together with C57BL/6 T cells (10 6 cells per mouse). Mice were then infected with PyV (2 Â 10 6 pfu) i.p 24 h later and serum samples were collected on day 21 after infection. Percentage of IgG2a/c-positive B cells in the spleens of the reconstituted mice was determined by FACS analysis of cells gated on B220 þ lymphocytes.
Biotinylated oligonucleotide DNA pull-down assays and chromatin immunoprecipitation assays (ChIP) Pull-down assays were done as described previously. 9 Briefly, nuclear lysates from HEK 293T cells transfected with IRF expressing plasmids for 48 h, were incubated with biotinylated oligodeoxynucleotide corresponding to IRF-5-IK or with a scrambled oligodeoxynucleotide and specifically bound IRF identified by western blots.
ChIP assay was done using the EZ ChIPTM chromatin immunoprecipitation kit (Millipore, Billerica, MA, USA) following manufacturer's recommendations. Purified, LPS-activated B cells (10 ug ml À 1 final) from B6 and Irf5 À / À mice were used for immunoprecipitation with IRF-specific antibodies. Primers used to amplify the IRF site in the Ikaros promoter were: F: 5 0 -GATCGGTACCCATTAGCTGCCGATGCCTGT-3 0 and R: 5 0 -GATCCTC GAGCCAAACGAGAGCTGTCTCTC-3 0 .
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